Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse, der evaluerer Atezolizumab, med eller uden Bevacizumab, hos patienter med uoperabelt hepatocellulært karcinom og Child-Pugh B7 og B8 cirrhose (Kirros)

6. november 2026 opdateret af: Genentech, Inc.

En fase II, open-label, multi-kohort, multicenter-undersøgelse i patienter med ikke-operabelt hepatocellulært karcinom og Child-Pugh B7 og B8 cirrhosis

The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

30

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Arizona
      • Tucson, Arizona, Forenede Stater, 85724
        • University of Arizona Cancer Center
    • California
      • La Jolla, California, Forenede Stater, 92093
        • UC San Diego Moores Cancer Center
      • Los Angeles, California, Forenede Stater, 90089-5601
        • University of Southern California-Keck School of Medicine -1975 Zonal Ave
      • Newport Beach, California, Forenede Stater, 92663
        • University of Southern California
      • Orange, California, Forenede Stater, 92868
        • University of California Irvine Medical Center
      • Pasadena, California, Forenede Stater, 91105-2561
        • California Liver Research Institute
      • Sacramento, California, Forenede Stater, 95817
        • University of California Davis Medical Center
      • Stanford, California, Forenede Stater, 94305
        • Stanford Health Care
      • Torrance, California, Forenede Stater, 90502-2006
        • Harbor UCLA Medical Center
      • West Hollywood, California, Forenede Stater, 90048-2422
        • Cedars Sinai Comprehensive Transplant Center
    • Connecticut
      • Hartford, Connecticut, Forenede Stater, 06106
        • Hartford Healthcare Cancer Institute at Hartford Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20037
        • George Washington University- Medical Faculty Associates
      • Washington D.C., District of Columbia, Forenede Stater, 20422-0001
        • Washington DC VA Medical Center
    • Florida
      • Orlando, Florida, Forenede Stater, 32806
        • Orlando Health Inc.
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611-2908
        • Northwestern University
      • Chicago, Illinois, Forenede Stater, 60612-4795
        • University of Illinois Health Outpatient Care Center
      • Chicago, Illinois, Forenede Stater, 60637-1426
        • The Duchossois Center for Advanced Medicine
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536-7001
        • University of Kentucky - Markey Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, Forenede Stater, 70805
        • LSU Health Baton Rouge
      • Baton Rouge, Louisiana, Forenede Stater, 70808-4300
        • Our Lady of the Lake Cancer Institute
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Forenede Stater, 02111
        • Tufts Medical Center
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48201
        • Barbara Ann Karmanos Cancer Institute
      • Detroit, Michigan, Forenede Stater, 48202
        • Henry Ford Health System
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64111
        • Saint Luke?s Hospital of Kansas City
    • New Jersey
      • New Brunswick, New Jersey, Forenede Stater, 08901
        • Rutgers Cancer Institute of New Jersey
      • Newark, New Jersey, Forenede Stater, 07103
        • Rutgers Cancer Institute of New Jersey at University Hospital
    • New York
      • Mineola, New York, Forenede Stater, 11501-4064
        • NYU Langone Hospital - Long Island
      • New York, New York, Forenede Stater, 10029
        • Icahn School of Medicine at Mount Sinai
      • The Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center
      • The Bronx, New York, Forenede Stater, 10468-3904
        • James J Peters Veterans Administration Medical Center - NAVREF
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Levine Cancer Institute
    • Ohio
      • Dayton, Ohio, Forenede Stater, 45428-9000
        • Dayton VA Medical Center - NAVREF - PPDS
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104-5020
        • The University of Oklahoma Health Sciences Center
    • Oregon
      • Hillsboro, Oregon, Forenede Stater, 97124-5806
        • Kaiser Permanente Westside Medical Center
      • Portland, Oregon, Forenede Stater, 97239-3011
        • OHSU Knight Cancer Institute Hematology Oncology
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Jefferson Health Honickman Center
      • Pittsburgh, Pennsylvania, Forenede Stater, 15240
        • Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
    • Tennessee
      • Germantown, Tennessee, Forenede Stater, 38138-1762
        • The West Clinic (East Campus)
      • Nashville, Tennessee, Forenede Stater, 37208-2918
        • Nashville General Hospital at Meharry
    • Texas
      • Dallas, Texas, Forenede Stater, 75390-0001
        • University of Texas Southwestern Medical Center
      • Dallas, Texas, Forenede Stater, 75246-2008
        • Texas Oncology (Worth) - USOR
      • Dallas, Texas, Forenede Stater, 75203-1260
        • Liver Institute at Methodist Dallas
      • Dallas, Texas, Forenede Stater, 75235
        • Moody Outpatient Center ? Parkland Health
      • Denison, Texas, Forenede Stater, 75020-0084
        • Texas Oncology - Denison Cancer Center
      • Houston, Texas, Forenede Stater, 77025-1669
        • Kelsey Research Foundation
      • Houston, Texas, Forenede Stater, 77030-4211
        • Michael E Debakey VA Medical Center - NAVREF - PPDS
    • Utah
      • Murray, Utah, Forenede Stater, 84107-5741
        • Intermountain Healthcare
      • St. George, Utah, Forenede Stater, 84790
        • Intermountain Cancer Center
    • Virginia
      • Falls Church, Virginia, Forenede Stater, 22042
        • Inova Schar Cancer Institute
      • Richmond, Virginia, Forenede Stater, 23226-1925
        • Bon Secours St. Mary's Hospital
      • Richmond, Virginia, Forenede Stater, 23298-5028
        • VCU Medical Center North Hospital
    • Washington
      • Seattle, Washington, Forenede Stater, 98101
        • Virginia Mason Medical Center
      • Rio Piedras, Puerto Rico, 00935
        • Pan American Center for Oncology Trials, LLC

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

General Inclusion Criteria:

  • Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
  • Disease that is not amenable to curative surgical and/or locoregional therapies
  • No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
  • Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
  • Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
  • Adequate hematologic and end-organ function
  • Life expectancy of at least 12 weeks
  • Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
  • Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
  • Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
  • Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
  • Serum bilirubin ≤ 3 × ULN
  • Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
  • Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
  • International normalized ratio (INR) ≤2.3

General Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
  • Treatment with systemic immunostimulatory agents
  • Treatment with systemic immunosuppressive medication
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
  • Inadequately controlled hypertension
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
  • Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
  • Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • Prior allogeneic stem cell or solid organ transplantation
  • Actively listed for liver transplantation
  • Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
  • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
  • Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
  • Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
  • History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
  • Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
  • Participants with ascites controlled on diuretics are allowed
  • History of spontaneous bacterial peritonitis within last 12 months

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Cohort A: Atezolizumab+Bevacizumab

Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator.

Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Andre navne:
  • Tecentriq; RO5541267

Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.

Andre navne:
  • Avastin; RO4876646
Eksperimentel: Cohort B: Atezolizumab

Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator.

Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Andre navne:
  • Tecentriq; RO5541267

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With Adverse Events (AEs)
Tidsramme: Baseline through the end of the study (up to approximately 36 months)

An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B.

Baseline through the end of the study (up to approximately 36 months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Trials, Hoffmann-La Roche

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. juli 2024

Primær færdiggørelse (Anslået)

30. juli 2027

Studieafslutning (Anslået)

30. december 2027

Datoer for studieregistrering

Først indsendt

18. oktober 2023

Først indsendt, der opfyldte QC-kriterier

18. oktober 2023

Først opslået (Faktiske)

24. oktober 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .